Faecal calprotectin in the assessment of Crohn's disease activity

Gaya, Daniel R.; Lyon, T. D. B.; Duncan, Andrew; Neilly, J. B.; Han, Seunghoon; Howell, Jamie B.; Liddell, Charly; Stanley, Adrian J.; Morris, Allan J.; MacKenzie, J. F.

doi:10.1093/qjmed/hci069

Cited by 76 publications

(56 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Correlation between fecal calprotectin concentration and mucosal pathology extension but not with the activity of the disease measured by clinical symptoms scores has also been emphasized by many authors [16,[19][20][21][22][23][24][25][26].…”

Section: Discussionmentioning

confidence: 99%

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Krzesiek¹

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Children constitute 20% of patients with inflammatory bowel diseases (IBD). Still there is a search for a perfect marker for this group of patients which would help in the diagnosis of the disease, in determinating its activity and in monitoring the treatment. Objectives. Evaluate the usefulness of the application of calprotectin measurement in stool samples from children with IBD, as a marker of the severity of inflammation. Material and Methods. We analysed 156 patients: 58 with ulcerative colitis (UC), 67 with Crohn's disease (CD), and 31 from the control group. In all patients the concentration of calprotectin in the sample of feces, markers of inflammation and hemoglobin were measured. Results. Concentration of calprotectin in feces of patients with IBD was above the normal range in all patients with moderate and severe disease and in the majority with mild disease or in remission, but it was normal in all patients from the control group. Conclusions. Elevated concentration of fecal calprotectin (FC) was observed in the majority of patients with IBD, but in none from the control group. The number of patients with elevated FC concentration increased together with the disease activity. FC concentration was higher in patients with severe and moderate disease activity. FC concentration in patients with IBD was associated with the increase of inflammatory markers and decreased haemoglobin. Percentage of laboratory abnormalities in children with Crohn's disease and perianal changes was higher. FC concentration can be a noninvasive marker of disease activity in IBD (Adv Clin Exp Med 2015, 24, 5, 815-822).

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Krzesiek¹

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Faecal calprotectin has been shown to correlate with disease activity in patients with IBD, but the sensitivity and specificity varies depending on the cutoff used. A cut-off of 100 µg/g has been shown to be most discriminatory in studies to date, [32][33][34][35] though other levels of calprotectin have been assessed. [36][37][38][39] …”

Section: Definition Of Active Diseasementioning

confidence: 99%

Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study

Garg

Burrell

Velkoska

et al. 2014

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Introduction:The relationship between intestinal inflammation and circulating components of the renin-angiotensin system (RAS) is poorly understood. Materials and methods: Demographic and clinical data were obtained from healthy controls and patients with inflammatory bowel disease (IBD). Plasma concentrations of the classical RAS components (angiotensin-converting enzyme (ACE) and angiotensin II (Ang II)) and alternative RAS components (ACE2 and angiotensin (1-7) (Ang (1-7))) were analysed by radioimmuno-and enzymatic assays. Systemic inflammation was assessed using serum C-reactive protein (CRP), white cell count, platelet count and albumin, and intestinal inflammation by faecal calprotectin. Results: Nineteen healthy controls (11 female; mean age 38 years, range 23-68), 19 patients with Crohn's disease (11 female; aged 45 years, range 23-76) and 15 patients with ulcerative colitis (6 female; aged 42 years, 26-64) were studied. Circulating classical RAS component levels were similar across the three groups, whereas ACE2 activity and Ang (1-7) concentrations were higher in patients with IBD compared to controls (ACE2: 21.5 vs 13.3 pmol/ml/min, p<0.05; Ang (1-7): 22.8 vs 14.1 pg/ml, p<0.001). Ang (1-7) correlated weakly with platelet and white cell counts, but not calprotectin or CRP, in patients with IBD. Conclusions: Circulating components of the alternative RAS are increased in patients with IBD.

show abstract

“…kalprotektyna, laktoferyna). Kalprotektyna dobrze koreluje z aktywnością zmian zapalnych w jelicie, zwłaszcza w przypadku lokalizacji zmian w jelicie grubym, i może być przydatna w monitorowaniu przebiegu ChLC [17][18][19].…”

Section: Mówi Się Wówczas O Nieokreślonym Zapaleniu Okrężni-cy (Indetunclassified

Guidelines for the management of Crohn’s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

Łodyga¹,

Eder²,

Bartnik³

et al. 2012

View full text Add to dashboard Cite

Faecal calprotectin in the assessment of Crohn's disease activity

Abstract: While the CDAI does not accurately reflect inflammatory activity in CD, a one-off FC reliably detects the presence or absence of intestinal inflammation in adult patients with CD, compared to WCS.

Cited by 76 publications

References 39 publications

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study

Guidelines for the management of Crohn’s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

Contact Info

Product

Resources

About